$RCKT News
Last published 3w ago
- 3w agoRCKTRocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare ConferenceBusiness WireRocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders,
- 1mo agoRCKTRocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor WebinarBusiness WireRocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development
- 1mo agoRCKTDanon Disease Program Update: RP-A501 Pivotal Phase 2 Trial - ROCKET PHARMACEUTICALS INCEarnings Call TranscriptsGood day, and welcome to the Rocket Pharmaceuticals Investor Program Update on Dana Disease and the RPA501 Pivotal Phase II Trial. As a reminder, today's program is being recorded. I will now turn the program over to Meg
- 1mo agoRCKTHTGCRocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules CapitalBusiness WireRocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders,
- 1mo agoRCKTRocket Pharmaceuticals at Morgan Stanley 24th Annual Global Healthcare Conference - ROCKET PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Goltz, one of the biotech analysts here. It's my pleasure to introduce Gaurav Shah, CEO of Rocket
- 1mo agoRCKTRocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon DiseaseBusiness WireFDA confirms pivotal efficacy population of 12 patients, including the first three treated under the modified protocol FDA review of initial safety data supports continued enrollment and dosing under modified
- 2mo agoRCKTRocket Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireRocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today
- 3mo agoRCKTRocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent ProgressBusiness WireAll three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic microangiopathy, capillary leak syndrome, or other
- 3mo agoRCKTRocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon DiseaseBusiness WireInitial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observed Rocket is actively engaging with the FDA to align on the path to pivotal trial completion;
- 5mo agoRCKTRocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 MillionBusiness WireRocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the
- 5mo agoRCKTRocket Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireRocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that
- 6mo agoRCKTRocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent ProgressBusiness WirePivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in
- 6mo agoRCKTRocket Pharmaceuticals Announces $180 Million Sale of Priority Review VoucherBusiness WirePRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline Cash runway extended into the second quarter of 2028 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated,
- 7mo agoRCKTRocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)Business WireFirst FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2 Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent
- 8mo agoRCKTRocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent ProgressBusiness WirePivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related
- 8mo agoRCKTRocket Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireRocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the
- 11mo agoBEAMCRSPRCKTSDGRBeyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat ConditionsPR NewswireEquity Insider News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrough approvals for gene therapies and mRNA...
- 11mo agoRCKTRocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare ConferenceBusiness WireRocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the
- 1y agoRCKTRocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent ProgressBusiness WirePivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date Leadership updates with the appointments of Dr. Syed Rizvi, Chief
- 1y agoRCKTRocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)Business WirePrescription Drug User Fee Act (PDUFA) target action date is March 28, 2026 All primary and secondary endpoints were met, and KRESLADI™ was well tolerated Rocket is eligible for a Rare Pediatric Disease
- 1y agoRCKTRocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireRocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that on
- 1y agoRCKTRocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoRCKTRocket Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireRocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the
- 1y agoRCKTRocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon DiseaseBusiness WireRocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the
- 1y agoRCKTInvestors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights – RCKTGlobeNewswireNEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT). Shareholders who purchased shares of RCKT during the class
- 1y agoRCKTRocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent ProgressBusiness WirePrioritizing development of RP-A501 (Danon disease), RP-A601 (PKP2-ACM), and RP-A701 (BAG3-DCM) to advance AAV cardiovascular gene therapy platform for sustained value creation FDA RMAT designation awarded to RP-A601
- 1y agoRCKTRocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - RCKTPR NewswireThe Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of...
- 1y agoRCKTRCKT Investors Have the Opportunity to Lead the Rocket Securities Fraud Lawsuit with Faruqi & Faruqi, LLPPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. ("Rocket" or the ...
- 1y agoRCKTInvestors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights - RCKTPR NewswireThe Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of...
- 1y agoRCKTSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket PharmaceuticalsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If
- 1y agoRCKTShareholders of Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights – RCKTGlobeNewswireNEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT). Shareholders who purchased shares of RCKT during the class
- 1y agoRCKTRocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights - RCKTPR NewswireThe Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of...
- 1y agoRCKTThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKTGlobeNewswireNEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT). Shareholders who purchased shares of RCKT during the class
- 1y agoRCKTRocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular ProgramsBusiness WireRestructuring pipeline to focus on AAV cardiovascular platform (Danon disease, PKP2-ACM, BAG3-DCM) and regulatory activities for KRESLADI™ (severe LAD-I), setting foundation for near- and long-term value
- 1y agoRCKTINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket PharmaceuticalsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired
- 1y agoRCKTRocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - RCKTPR NewswireThe Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of...
- 1y agoRCKTRocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic CardiomyopathyBusiness WireRocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the
- 1y agoRCKTRocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights – RCKTGlobeNewswireNEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT). Shareholders who purchased shares of RCKT during the class
- 1y agoRCKTThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKTPR NewswireThe Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of...
- 1y agoRCKTSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket PharmaceuticalsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you
- 1y agoRCKTInvestors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights - RCKTPR NewswireThe Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of...
- 1y agoRCKTSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket PharmaceuticalsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. ("Rocket" or the ...
- 1y agoRCKTRocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated CardiomyopathyBusiness WireRP-A701 is a first-in-class gene therapy for the treatment of BAG3-associated dilated cardiomyopathy BAG3-associated dilated cardiomyopathy is a rare, inherited heart condition caused by mutations in the BAG3 gene,
- 1y agoRCKTRCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLPGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you
- 1y agoRCKTRCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLPPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. ("Rocket" or the ...
- 1y agoRCKTINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket PharmaceuticalsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you
- 1y agoRCKTRocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - RCKTPR NewswireThe Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of...
- 1y agoPHVSRCKTNodThera Announces Appointment of Elisabeth Björk as Board MemberGlobeNewswireNodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and
- 1y agoRCKTInvestors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights - RCKTPR NewswireThe Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of...
- 1y agoRCKTINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket PharmaceuticalsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. ("Rocket" or the ...